The Expression of Forkhead Box P3 T Regulatory Lymphocytes as a Prognostic Factor in Malignant Melanomas.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
09 Jun 2024
Historique:
received: 29 04 2024
revised: 26 05 2024
accepted: 05 06 2024
medline: 27 6 2024
pubmed: 27 6 2024
entrez: 27 6 2024
Statut: epublish

Résumé

Since transcription factor Forkhead Box P3 (FoxP3) was identified as a specific regulatory T cell (Treg) marker, researchers have scrutinized its value as a potential novel therapeutic target or a prognostic factor in various types of cancer with inconsistent results. The present analysis was performed to assess the influence of Treg FoxP3 expression on the prognosis of primary melanoma and to evaluate the correlations with various clinicopathological prognostic factors. We analyzed all eligible patients with stage pT3 primary malignant melanomas treated in a tertiary cancer center. Immunohistochemical staining for Treg FoxP3 expression was performed on retrospectively identified paraffin blocks and subsequently correlated with the outcomes of the patients. A total of 81% of the patients presented a positive Treg FoxP3 expression, being correlated with a higher risk of lymph node metastasis, tumor relapse, and death. Moreover, positive expression was statistically associated with a shorter OS. The tumor relapse rate was estimated at 36.7%. A positive expression of Treg FoxP3 and lymph node metastasis were associated with a higher risk of death based on multivariate analysis. Treg FoxP3 expression may be used as an independent prognostic factor in patients with malignant melanoma to evaluate tumor progression and survival.

Identifiants

pubmed: 38928083
pii: ijms25126377
doi: 10.3390/ijms25126377
pii:
doi:

Substances chimiques

Forkhead Transcription Factors 0
FOXP3 protein, human 0
Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Vlad Alexandru Gâta (VA)

Department of Surgical Oncology and Gynecologic Oncology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
"Prof. Dr. Ion Chiricuță" Institute of Oncology, 400015 Cluj-Napoca, Romania.

Andrei Pașca (A)

Department of Surgical Oncology and Gynecologic Oncology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
"Prof. Dr. Ion Chiricuță" Institute of Oncology, 400015 Cluj-Napoca, Romania.

Andrei Roman (A)

"Prof. Dr. Ion Chiricuță" Institute of Oncology, 400015 Cluj-Napoca, Romania.
Department of Radiology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.

Maximilian Vlad Muntean (MV)

"Prof. Dr. Ion Chiricuță" Institute of Oncology, 400015 Cluj-Napoca, Romania.
Department of Plastic and Reconstructive Surgery, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.

Dragoș Ștefan Morariu (DȘ)

"Prof. Dr. Ion Chiricuță" Institute of Oncology, 400015 Cluj-Napoca, Romania.

Eduard Alexandru Bonci (EA)

Department of Surgical Oncology and Gynecologic Oncology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
"Champalimaud" Research and Clinical Centre, 1400-038 Lisbon, Portugal.

Constantin Dina (C)

Department of Anatomy, Faculty of Medicine, Ovidius University, 900470 Constanta, Romania.

Loredana Ungureanu (L)

Department of Dermatology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Department of Dermatology, Emergency County Hospital Cluj-Napoca, 400006 Cluj-Napoca, Romania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH